BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor conferences:
A live webcast of the presentation and fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the events will also be available for a limited time.
About Inozyme Pharma
Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in multiple clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
For more information, please visit www.inozyme.com or follow Inozyme on LinkedIn, X (formerly Twitter), and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com
Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com
Company not implementing a reverse split at this timeTop line results forthcoming for company's phase…
BAY HARBOR ISLANDS, FL / ACCESSWIRE / April 8, 2024 / Dr. Anatoly Ripa, a…
These contracts cap a record first quarter at Cloud DX, which has announced 10 new…
Vancouver, British Columbia--(Newsfile Corp. - April 9, 2024) - AgriCann Solutions Corp. ("AgriCann") (with its…
Oakville, Ontario--(Newsfile Corp. - April 9, 2024) - Xediton Pharmaceuticals Inc., a leading Canadian specialty…
DENVER--(BUSINESS WIRE)--Emet Surgical, developers of innovative tools to improve surgery outcomes, today announced its acceptance…